SanBio Co Ltd represents the values of innovation, collaboration, and patient-centricity. With a corporate philosophy focused on advancing regenerative medicine, SanBio is committed to developing novel therapies that address unmet medical needs. By leveraging their proprietary technology, SB623, SanBio aims to restore function and improve the quality of life for patients suffering from neurological disorders. Their dedication to scientific excellence, ethical conduct, and transparency fosters trust among stakeholders. Through their pioneering research and development efforts, SanBio Co Ltd is contributing to advancements in the field of regenerative medicine, bringing hope to patients worldwide.

SanBio Co Ltd is primarily present in Japan.

Some significant milestones achieved by SanBio Co Ltd include the successful completion of Phase II clinical trials for their investigational therapeutic product SB623, which showed promising results in treating motor deficits caused by stroke. Additionally, SanBio Co Ltd received Fast Track designation from the U.S. FDA for SB623, recognizing its potential to address unmet medical needs. The company also expanded its product pipeline and entered into collaborations with global pharmaceutical companies to further advance their regenerative medicine technologies. SanBio Co Ltd continues to strive towards making notable advancements in the field of regenerative medicine and improving patient outcomes.

SanBio Co Ltd is a pioneering regenerative medicine company based in Japan. Founded in 2005, SanBio focuses on developing and commercializing groundbreaking cell-based therapies for neurological disorders. With a strong commitment to advancing scientific research, SanBio has made significant strides in neurorehabilitation and regenerative medicine. The company has successfully conducted clinical trials and received approvals from regulatory authorities, demonstrating the effectiveness and safety of its innovative therapies. SanBio's dedication to improving patients' lives through cutting-edge treatments has earned it a prominent position in the field of regenerative medicine.

SanBio Co Ltd faces competition from pharmaceutical companies that operate in the regenerative medicine field. Some of the main competitors include Mesoblast Limited, Athersys Inc., and Healios K.K. These companies are also focused on developing innovative therapies for treating neurological disorders and injuries, similar to SanBio. However, SanBio has established its unique position in the market with its proprietary regenerative cell therapy products.

SanBio Co Ltd is primarily active in the biotechnology and pharmaceutical industries.

The business model of SanBio Co Ltd focuses on developing and commercializing regenerative medicine products. SanBio Co Ltd specializes in the research and development of innovative cell therapies to treat neurological disorders. With a strong emphasis on stem cell-based therapies, the company aims to provide effective and safe treatments for conditions such as traumatic brain injury, stroke, and chronic motor deficits. Through its extensive research, partnership collaborations, and dedication to clinical trials, SanBio Co Ltd aims to revolutionize the field of regenerative medicine and improve the quality of life for patients worldwide.

Коефициентът на цена спрямо печалбата (КЦП) на SanBio Co е -24,21.

Коефициентът на цена към оборот (KUV) на SanBio Co е 0.

AlleAktien качественият резултат за SanBio Co е 2/10.

Приходите не могат да бъдат изчислени в момента за SanBio Co.

SanBio Co печалба е -2,64 млрд. JPY.

SanBio Co Ltd is a biopharmaceutical company specializing in the development and commercialization of innovative therapies for neurological diseases. It was originally founded in Japan and its business model includes research and development, clinical trials, partnerships, and distribution. The research and development team at SanBio focuses on developing novel drugs and therapies based on stem cell and genomic research. They utilize state-of-the-art technologies to identify and optimize novel drug candidates to enable successful treatment of neurological diseases. SanBio is committed to conducting clinical trials by partnering with renowned medical centers and research institutions in Japan, the US, and Europe. This collaboration aims to confirm the effectiveness and safety of clinical candidates for broad use in healthcare. SanBio has also formed partnerships with other companies worldwide for the marketing and distribution of its products. These partnerships aim to make SanBio's products and therapies accessible globally. SanBio offers various therapy products for neurological diseases, including "SB623" for traumatic brain injury and "SB509" for Amyotrophic Lateral Sclerosis (ALS). SB623 is being developed to treat patients with skull-brain injuries. It is a cell therapy derived from reprogrammed human neural stem cells from a donor's bone marrow. SB509 is being developed for the treatment of ALS and is a gene therapy that produces neurotrophic factors to promote the survival of motor neurons. Both products have the potential to meet the need for effective therapies for neurological diseases. In summary, SanBio Co Ltd offers innovative therapeutics for the treatment of neurological diseases. The company's business model includes research and development of novel therapies, conducting clinical trials, partnerships, and product distribution. SanBio has the commitment and resources to meet the demand for effective therapeutics for treating neurological diseases.

SanBio Co разпределя дивидента от 0 JPY на плащания годишно.

Дивидентата за SanBio Co в момента не може да бъде изчислена или компанията не разпределя дивиденти.

ISIN на SanBio Co е JP3336750009.

WKN на SanBio Co е A14SRH.

Тикерът на SanBio Co е 4592.T.

През последните 12 месеца SanBio Co изплати дивиденда в размер на . Това съответства на дивидендна доходност от около . За следващите 12 месеца се очаква SanBio Co да изплати дивиденда в размер на 0 JPY.

Дивидентната доходност на SanBio Co в момента е .

SanBio Co изплаща дивидент на тримесечие. Той се разпределя в месеците .

SanBio Co платеше дивиденда всяка година през последните 0 години.

За идните 12 месеца се очакват дивиденти в размер на 0 JPY. Това съответства на дивидентна доходност от 0 %.

SanBio Co се отнася за сектор 'Здраве'.

За да получите последното дивидентно плащане от SanBio Co на 6.09.2024 г. в размер на 0 JPY, трябваше да притежавате акцията в портфейла си преди Ex-деня на 6.09.2024 г..

Последното дивидентно плащане беше извършено на 6.09.2024 г..

През година 2023 SanBio Co изплати 0 JPY под формата на дивиденти.

Дивидентите от SanBio Co се изплащат в JPY.